Quarterly ResultAug 6, 2026, 05:19 PM
Outset Medical Q2 Net Loss Narrows to $18.0M
AI Summary
Outset Medical, Inc. reported a net loss of $18.0 million for the second quarter of 2026, an improvement from $18.5 million in the prior year period, while total revenue slightly increased to $31.6 million. For the six months ended June 30, 2026, the net loss narrowed to $37.0 million from $44.3 million, despite a slight decrease in total revenue to $59.5 million. The company also noted ongoing stockholder class action lawsuits and an amendment to its Perceptive Credit Agreement.
Key Highlights
- Q2 2026 net loss narrowed to $18.0 million from $18.5 million YoY.
- Q2 2026 total revenue slightly increased to $31.6 million.
- Six-month net loss improved to $37.0 million from $44.3 million YoY.
- Six-month total revenue decreased to $59.5 million from $61.2 million YoY.
- Net cash used in operating activities for six months reduced to $22.5 million.
- Cash, equivalents, restricted cash, and short-term investments totaled $151.0 million.
- Ongoing stockholder class action lawsuits regarding Tablo Hemodialysis System.
- Amended Perceptive Credit Agreement, resetting warrant exercise price to $4.838.
Price Impact
More from OM